Startup Genia Sees Diagnostic Potential for Nanopore Sequencing Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genia, a Mountain View, Calif.-based startup, is developing a semiconductor-based nanopore sequencing platform that it believes will show promise for molecular diagnostic applications.

Stefan Roever, CEO and founder of the company, told GenomeWeb Daily News this week that the company has an alpha version of its single-molecule platform in hand and is currently optimizing the biochemistry for a beta system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.